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with IgA nephropathy.
Background. Clinical manifestation of IgA nephropathy
(IgAN) strikingly occurs after respiratory tract infections. An
intestinal inflammation has also been described. We hypothe-
sized that the intestinal inflammation should manifest itself as
an increase in inflammatory cells and mucosal cyclooxygenase
2 (COX-2) expression.
Methods. By using immunohistochemistry, we determined
the phenotype and quantity of inflammatory cells in duode-
nal biopsy specimens from 17 IgAN patients. Control material
comprised 18 patients undergoing gastroscopy because of dys-
pepsia.
Results. All the biopsy specimens disclosed normal villous ar-
chitecture. In IgAN, CD3+ cells and COX-2–positive cells were
significantly increased and J chain–producing plasma cells were
significantly decreased. CD3+ cells coexpressed COX-2 protein
and COX-2–positive cells also expressed CD45RO antigen. The
number of lymphocytes correlated significantly with serum IgA
and COX-2-expression with serum IgA and the degree of hema-
turia. COX-2–positive subepithelial fibroblasts were a conspic-
uous finding in IgAN. In CD68+ and CD15+ cells, a significant
increase was seen. Many of these cells also expressed COX-2
protein. CD15+ positivity correlated significantly with protein-
uria in IgAN.
Conclusion. Our results indicate that small bowel inflamma-
tion in IgAN shows itself as an increased number of mucosal
inflammatory cells. However, polymeric IgA production is sig-
nificantly decreased. An increased mucosal COX-2 expression
suggests activation of the inflammatory cells and the degree of
inflammation significantly correlates with serum IgA and the
amount of proteinuria and hematuria. Subepithelial fibroblasts
seem also to be involved in the inflammatory reaction.
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Despite intensive research, the pathogenesis of IgA
nephropathy (IgAN) has remained unresolved. Because
clinical manifestation and exacerbations of the disease
strikingly coincide with mucosal infections, especially
those of the upper respiratory tract, there is good rea-
son to assume that mucosal sites are strongly involved.
Existing evidence also suggests that the intestinal mu-
cosa is one of the sites involved in the immune response
leading to the pathognomonic deposition of IgA in the
kidney glomeruli [1, 2].
IgAN has been proposed to result from hyperactivity
of the mucosal immune system [3]. In concordance, the
number of mucosal inflammatory cells has been shown to
be increased in the small bowel of IgAN patients [4, 5]. An
increase in the human leukocyte antigen (HLA) class II
antigen DR, reflecting intestinal immune activation, has
also been described [4]. T-cell activation and high serum
levels of T-cell–derived cytokines are also characteristic
of primary IgAN [6–8]. On this basis, the conclusion that
IgAN patients have an ongoing intestinal inflammation
of varying degree is justified. However, a clear decrease
in the duodenal J chain–producing plasma cells in IgAN
argues against the small bowel mucosa of being the source
of glomerular IgA deposits [9].
During inflammation, proinflammatory cytokines typ-
ically induce the production of cyclooxygenase-2
(COX-2), which further catalyses the production of
proinflammatory prostaglandins [10, 11]. Levels of COX-
2 are normally low, but in various inflammatory disorders,
including those in the gastrointestinal tract, local expres-
sion of COX-2 has been shown to increase remarkably
[12–14].
On the basis of the results of previous studies, we hy-
pothesized that intestinal inflammation in IgAN should
manifest itself as an increase in the number of inflamma-
tory cells and increased COX-2 expression in the mucosal
cells participating in the inflammatory reaction. Studies
concerning intestinal COX-2 expression in IgAN have
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Table 1. Clinical findings in patients with IgA nephropathy (IgAN) at the time of small bowel biopsy
Mesangial
immunofluorescence
Serum Serum Systemic findingsc
Gender/ creatinine IgA Proteinuria Hematuria findings
Patient age lmol/L g/L g/24 hours stix Hypertensiona in historyb IgA C3 IgG IgM
1 F/46 81 3.52 0.18 2+ Yes No 3+ 2+ − 1+
2 M/41 102 3.34 0.92 1+ No No 2+ 1+ − −
3 M/38 92 3.69 0.28 2+ No No 3+ 3+ 1+ 1+
4 F/27 71 — 2.25 2+ No 1 3+ 2+ − 1+
5 M/31 772 5.04 — 3+ Yes No 3+ 2+ − −
6 M/20 102 2.78 0.23 1+ No No 3+ 1+ − 1+
7 M/41 92 3.28 0.15 − No No 3+ 2+ − −
8 F/56 100 5.80 0.38 3+ Yes 1 3+ 1+ 2+ −
9 M/21 86 2.22 0.79 3+ No 1 3+ 2+ − −
10 F/24 57 3.04 0.14 − No No 2+ 2+ 1+ −
11 M/44 87 2.75 0.15 2+ No No 3+ 1+ − −
12 M/21 87 2.90 0.17 1+ Yes 2 3+ 2+ − −
13 F/60 116 1.70 7.18 3+ Yes No 2+ 2+ − −
14 M/41 117 4.12 1.05 2+ Yes No 3+ 2+ − −
15 M/43 76 2.92 0.92 2+ No No 3+ 1+ − −
16 M/41 229 — 4.30 1+ Yes No 3+ 3+ − −
17 M/62 114 2.80 2.20 1+ Yes 2 3+ 2+ − −
aBlood pressure P > 140/90 mm Hg or antihypertensive medication in use; b1, purpuric rash; 2, purpuric rash and abdominal symptoms; cfluorescence intensity was
graded from negative (−) to strong positive (3+).
not been previously published. In the present study, we
determined the phenotype of mucosal cells and their re-
lation to typical clinical laboratory parameters of IgAN in
duodenal biopsy specimens from 17 patients with IgAN.
METHODS
Patients and controls
The patients with IgAN included 12 males and five
females aged from 20 to 62 years (mean 37 years)
(Table 1). The diagnosis of IgAN was based on histo-
logic and immunofluorescence findings [15]. In 11 pa-
tients, solitary mesangial IgA and C3 deposits were seen;
the others also had additional glomerular findings. All
patients had clinical nephritis (i.e., proteinuria and mi-
croscopic hematuria), and blood pressure was elevated
in eight cases. Five patients had had purpuric rash and
two of these had also had abdominal symptoms. The clin-
ical picture suggested Henoch-Scho¨nlein syndrome, but
no one had arthritis. Gastroscopic examination and small
bowel biopsy were performed within one year of renal
biopsy. Clinical laboratory data of the patients at the time
of small bowel biopsy are shown in Table 1. At that time
no patient suffered from any clinical systemic symptoms
of Henoch-Scho¨nlein syndrome, and no patient received
corticosteroids or immunosuppressive drugs.
The controls comprised small bowel biopsy specimens
from 18 patients undergoing gastroscopy because of dys-
pepsia.
The study protocol was approved by the Ethics Com-
mittee of Tampere University Hospital.
Biopsy specimens
Renal biopsy specimens were initially studied by
routine histopathologic techniques. Immunofluorescence
microscopy was used to localize IgG, IgA, IgM, comple-
ment (C1q and C3), fibrinogen, kappa chains, lambda
chains, and albumin.
Small bowel biopsy was carried out with upper endo-
scopic examination. From the distal part of the duodenum
six specimens were taken. Three specimens were embed-
ded in paraffin and three were frozen in liquid nitrogen
after embedding in O.C.T compound (Miles Inc., Elkhart,
IN, USA). The frozen specimens were stored at −70◦C.
Routine hematoxylin and eosin staining was used to de-
termine morphologic details of the specimens.
Immunohistochemistry
The following monoclonal antibodies were used for
immunohistochemical staining of the mucosal cells: anti-
CD3 (clone PS1) (Novocastra Laboratories Ltd., New-
castle upon Tyne, UK) (1:40), anti-CD45RO (clone
UCHL1) (Dako Cytomation Denmark A/S, Glostrup,
Denmark) (1:800), anti-CD15 (clone MMA) (Becton
Dickinson Immunocytometry Systems, San Jose, CA,
USA) (1:20), anti-CD68 (clone PG-M1) (Dako Cytoma-
tion Denmark A/S) (1:1500), anti-J chain (clone M19/9J)
(Chemicon International, Temecula, CA, USA) (1:50),
and anti a-smooth muscle actin (a-SMA) (clone 1A4)
(Lab Vision Corporation, Fremont, CA, USA) (1:800).
Polyclonal anti-IgA (Dako Cytomation Denmark A/S)
(1:5000) and antivimentin (Biogenex, San Ramon, CA,
USA) (1:40000) were also used.
COX-2 was localized using a monoclonal antibody
(anti-COX-2) (clone 33) (Transduction Laboratories,
Lexington, KY, USA) (1:100) that recognizes the
C terminus of COX-2 protein. Proliferation activity of
the mucosal cells was determined by staining the Ki-67
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antigen (anti-Ki-67) (clone MIB-1) (Dako Cytomation
Denmark A/S) (1:100).
For light microscopic immunoperoxidase staining,
3 lm paraffin sections were cut onto ChemMateTM
capillary gap microscope slides (Dako Cytomation Den-
mark A/S). Antigen retrieval for CD3, CD15, CD45RO,
CD68, vimentin, IgA, and J chain was performed on
rehydrated sections in a microwave oven at 850 W for two
7-minute cycles using Tris-ethylenediaminetetraacetic
acid (EDTA) buffer (pH 9.0) as the retrieval solution.
a-SMA was stained without any pretreatment. Immunos-
taining was carried out in a TechMateTM 500 Immunos-
tainer (Dako Cytomation Denmark A/S) using the
labeled avidin-biotin-peroxidase technique or the
EnVisionTM polymer technique (Dako Cytomation
Denmark A/S). Diaminobenzidine (DAB) was used as
a chromogen and haematoxylin as a nuclear stain. The
specificity of immunohistochemistry was controlled by
omitting the primary antibodies or replacing them with
irrelevant antisera. Known positive tissue samples were
also used to confirm the staining reliability of all separate
staining batches.
Confocal microscopy (UltraVIEW Confocal Imaging
System; PerkinElmer Life Sciences Inc., Boston, MA,
USA and Carl Zeiss LSM 510 Meta, Carl Zeiss Mi-
croscopy, Jena, Germany) was used to determine the
cell types expressing COX-2 protein. For this purpose,
double fluorescence immunostaining was performed by
hands on paraffin sections. COX-2 was colocalized with
CD3, CD45RO, CD15, and CD68. After antigen re-
trieval, primary monoclonal mouse anti-COX-2 anti-
body (Transduction Laboratories) was localized by using
Alexa-Fluor 555-conjugated anti-mouse IgG1 (Molec-
ular Probes, Inc., Eugene, OR, USA). Primary anti-
bodies to CD3 and CD45RO were detected by using
Alexa-Fluor 488–conjugated antimouse IgG2a (Molec-
ular Probes, Inc.). Primary antibodies to CD15 were
revealed by using Alexa-Fluor 488–conjugated anti-
mouse IgM (Molecular Probes Inc.) and to CD68 by using
Alexa-Fluor 488–conjugated antimouse IgG3 (Molecu-
lar Probes, Inc.).
Quantification of immunohistochemically stained cells
Double fluorescence immunostaining results were in-
vestigated by confocal microscopy at a magnification of
×1000. The cell counts were not quantified. Immunoper-
oxidase staining results were investigated at a magnifica-
tion of ×400 and cell counts were obtained from at least
15 consecutive microscopic fields as follows:
The numbers of intraepithelial CD3+ and COX-2-
positive cells were expressed as number of cells per mm
of the length of epithelium. The length was measured us-
ing an image analysis program (AnalySIS) (Soft Imaging
System GmbH, Mu¨nster, Germany). Because only oc-
casional intraepithelial CD45RO+, CD15+, and CD68+
cells were seen, their amounts were not quantified.
In the lamina propria, CD3+, CD15+, COX-2–positive
cells, IgA plasma cells and J chain–positive plasma cells
were counted as the number of cells per mm2 of lamina
propria. The area of the lamina propria was determined
by point counting using a 100-point square lattice in the
eyepiece [16]. The amount of CD68+ cells in the lamina
propria was graded from 0 (negative) to 6 (strong posi-
tive), because their staining pattern made it impossible to
obtain exact cell numbers. The number of polymeric IgA
producing plasma cells was expressed as the percentage
of J chain–positive cells of all IgA producing plasma cells.
The proportion of COX-2–positive subepithelial fi-
broblasts along the basement membrane under the vil-
lous epithelium was measured using an image analysis
program (AnalySIS). The amount of COX-2–positive fi-
broblasts was expressed as the percentage covering of
the total basement membrane length measured. Numeri-
cal evaluation of these fibroblasts was difficult because of
their elongated cell morphology. The results of numeri-
cal evaluation and percentage cover, however, correlated
significantly in both IgAN (r = 0.823, P < 0.001) and con-
trol specimens (r = 0.965, P < 0.001).
Statistical analysis
Statistical analyses were performed with the Superior
Performance Software System (SPSS). In the analyses,
paired and unpaired t tests were used. Data concerning
CD68 were analyzed using the Mann-Whitney U test.
Correlation between different staining results was eval-
uated using Pearson’s correlation coefficient (r) but the
ordinal scale data concerning CD68 was analyzed using
Spearman’s correlation coefficient (rs).
The coefficients of intra-observer variation of CD3+,
CD15+, CD68, IgA, J chain and COX-2 counts were
0.990, 0.967, 0.935, 0.956, 0.992, and 0.977, respectively.
The interobserver coefficient of variation (rs) of COX-2
positivity in the fibroblasts was 0.971.
RESULTS
The small bowel mucosa of all patients were macro-
scopically normal. In microscopic investigation, the
biopsy specimens also disclosed normal villous architec-
ture. Results from the patients with features of Henoch-
Scho¨nlein syndrome in history did not differ from those
with primary IgAN (Table 1).
In the small bowel epithelia of the IgAN patients,
the number of CD3+ cells was significantly increased
(Fig. 1A), as was the number of intraepithelial COX-
2–positive cells (Fig. 1B). Occasional intraepithelial
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Fig. 1. Differences in small bowel mucosal cell numbers in IgA nephropathy (IgAN) and control specimens. Box plot. (A) Intraepithelial CD3-
positive cells. (B) Intraepithelial cyclooxygenase-2 (COX-2)–positive cells. (C) COX-2–positive subethelial fibroblasts. (D) CD3 in the lamina
propria. (E) COX-2 in the lamina propria. (F) Polymeric Iga producing plasma cells. (G) CD68 in the lamina propria. (H) CD15 in the lamina
propria. Bars show median, quartiles and extreme values. Extreme values are marked with the respective patient numbers in Table 1.
CD45RO+ and CD68+ cells were also seen. COX-2–
positive cells were morphologically lymphocytes and
there was a significant correlation between CD3 and
COX-2 positivity (r = 0.801, P < 0.001). In confocal mi-
croscopy, a large proportion of intraepithelial CD3+ cells
proved to be COX-2–positive.
In cases of IgAN, COX-2 positivity in the subepithe-
lial fibroblasts was a conspicuous finding (Fig. 2A). In the
villi, the proportion of COX-2–positive fibroblasts was
significantly higher in cases of IgAN than in the controls
(Fig. 1C). In the crypt areas, there was no difference in
the COX-2 expression between IgAN and control speci-
mens. COX-2 positivity of subepithelial fibroblasts in the
villi correlated significantly with COX-2 positivity in the
lamina propria (r = 0.842, P < 0.001). In both IgAN
and control specimens, subepithelial fibroblasts were a-
SMA–positive mainly in the crypts, whereas vimentin ex-
pression was seen both in the crypts and the villi.
In the lamina propria, the number of CD3+ cells was
significantly increased in cases of IgAN (Figs. 1D and
2B). An equal increase in the amount of COX-2–positive
cells was observed (Figs. 1E and 2A), and there was sig-
nificant correlation between CD3 and COX-2 positivity
(r = 0.791, P = 0.001). CD3 positivity in the lamina pro-
pria also correlated significantly with intraepithelial CD3
(r = 0.729, P = 0.002) and COX-2 positivity (r = 0.799,
P = 0.001). A significant correlation was observed be-
tween the number of CD3+ cells in the lamina propria
and the amount of serum IgA (r = 0.801, P = 0.001).
Serum IgA also correlated significantly with COX-2 pos-
itivity in the epithelium (r = 0.578, P = 0.024) and lamina
propria (r = 0.605, P = 0.009). COX-2 expression in the
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Fig. 2. Immunoperoxidase staining of the small bowel mucosa in cases
of IgA nephropathy (IgAN). (A) Cyclooxygenase-2 (COX-2)–positive
cells are diffusely distributed in the lamina propria. Strong COX-2 ex-
pression is also present in the subepithelial fibroblasts along the villous
basement membrane. (B) CD3+ cells are numerously present intraep-
ithelially and in the lamina propria. (C) Nuclear Ki-67 antigen expres-
sion is exclusively present in the cryptal epithelial cells. (D) CD68+ cells
are diffusely distributed in the lamina propria.
lamina propria also correlated significantly with the de-
gree of hematuria (r = 0.546, P = 0.043). Staining of Ki-67
antigen indicated proliferation in only cryptal epithelial
cells (Fig. 2C).
In confocal microscopy, a remarkable proportion of
CD3+ cells coexpressed COX-2 protein (Fig. 3A) and
a considerable number of COX-2–positive cells also ex-
pressed CD45RO antigen (Fig. 3B).
In the number of IgA producing plasma cells, there
was no difference between IgAN and controls. On the
contrary, the number of J chain producing plasma cells
was significantly decreased in IgAN (P < 0.001) as was
the proportion of polymeric IgA producing plasma cells
(P < 0.001) (Fig. 1F). A significant correlation was seen
between IgA plasma cells and serum IgA (r = 0,548,
P = 0.034). In the number of polymeric IgA producing
plasma cells, there was a significant negative correlation
with COX-2 positivity in the lamina propria (r = −0.692,
P = 0.009) and epithelium (r = −0.558, P = 0.028).
Fig. 3. Double fluorescence confocal microscopy of the small bowel
mucosa in cases of IgA nephropathy (IgAN). (A) Expression of CD3
(green) and cyclooxygenase-2 (COX-2) (red); coexpression is present
in two cells. (B) Expression of CD45RO (green) and COX-2 (red);
coexpression is present in one cell. Colocalization of both antigens is
seen as yellow. (C) Coexpression of CD68 (green) and COX-2 (red) in
three cells. Colocalization of both antigens is seen as yellow. (D) COX-2
expression (red) in two cells, the other of which is also CD15-positive
(green).
In the lamina propria, infiltration of CD68+ cells was
observed (Fig. 2D). Compared with the controls, there
was a significant increase (Fig. 1G). Significant corre-
lation was observed between CD68 and CD3 positivity
(rs = 0.702, P = 0.002), and between CD68 and COX-2
positivity (rs =0.744, P =0.001). In several CD68 antigen-
bearing cells, COX-2 expression was seen in confocal
microscopy (Fig. 3C).
CD15+ cells in the lamina propria were not numerous,
but there was a significant difference between IgAN and
control specimens (Fig. 1H). CD15 positivity correlated
significantly with CD3 positivity (r = 0.681, P = 0.003)
and COX-2 expression in the subepithelial fibroblasts
(r = 0.742, P = 0.001). CD15 positivity in the lamina pro-
pria also correlated significantly (r = 0.764, P = 0.001)
with the degree of proteinuria in IgAN patients. In sev-
eral CD15+ cells, confocal microscopy disclosed COX-2
expression (Fig. 3D).
DISCUSSION
In IgAN, there is a great paucity of studies of the in-
testine, and accordingly, immune reactions of the small
bowel mucosa have also remained poorly understood.
In the present study, we demonstrated that the num-
bers of lymphocytes (CD3+) and monocyte-macrophages
(CD15+ and CD68+) were significantly increased in the
small bowel mucosae of IgAN patients. On the con-
trary, J chain producing plasma cells were significantly
decreased. We also report that the inflammation was
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reflected in significantly increased COX-2 expression in
the inflammatory cells in the lamina propria. Both the
number of CD3+ cells and COX-2 expression strongly
correlated with serum IgA level. COX-2 expression in the
lamina propria further correlated with the degree of
hematuria. Significant correlation was also seen between
the number of CD15+ cells and the amount of protein-
uria. Interestingly, significant COX-2 production was also
seen in the subepithelial fibroblasts.
In our previous study, we have described a significant
increase in the numbers of intraepithelial lymphocytes in
the small bowel of IgAN patients [4]. This result was later
confirmed by Rostoker, Delchier, and Chaumette [5]. Al-
though lymphocytes and cytokines have a central role
in the intestinal immune response, nonmarrow-derived
lamina propria stromal cells have also proved to be im-
portant in this respect [17]. In IgAN, our results indicated
significantly increased COX-2 expression in subepithelial
fibroblasts, the location of which was consistent with that
described as being typical of myofibroblasts [18–20]. An
emerging view of fibroblasts is that, in concert with other
mesenchymal cells, they can function as regulators of the
inflammatory response [21]. At the interface between the
epithelium and lamina propria, fibroblasts can also modu-
late the cross-talk between these compartments and play
a role in mucosal immunity [22–24].
We saw prominent COX-2 production in subepithelial
fibroblasts in the villi, but no expression of a-SMA, an
activation marker of myoepithelial fibroblasts [23]. Fi-
broblasts positive for a-SMA were sporadically present
around the crypts. In contrast, subepithelial fibroblasts
were all vimentin-positive, suggesting that vimentin-type
myofibroblasts [23] produce COX-2 protein in the small
bowel. The role of these cells in the inflammatory pro-
cess remains to be clarified. However, fibroblasts have
been shown to express inducible COX-2 in a variety of
tissues [21, 25–27]. During both acute and chronic intesti-
nal inflammation, myofibroblasts have been observed to
be sites of COX-2–derived prostaglandin synthesis [24,
28]. One factor triggering this type of response is infec-
tion [29, 30].
Chemokines produced by fibroblasts are able to attract
bone marrow–derived cells [21], which can again activate
fibroblasts. Activated fibroblasts can release regulatory
molecules, which can strongly influence the behavior of
neighboring cells. Contacts between lymphocytes and fi-
broblasts can stimulate enhanced COX-2 expression and
consequent prostaglandin production [31]. In the small
bowel lamina propria of IgAN patients, we saw a signif-
icant increase in CD3+ cells and our results further indi-
cated a significant correlation between COX-2–positive
fibroblasts and COX-2 positivity in the lamina propria
(r = 0.842, P < 0.001). In addition, we found a significant
correlation between COX-2 expression in the fibroblasts
and the number of monocytes infiltrating the lamina pro-
pria. In line with previous literature [21, 23, 32, 33], our
present findings suggest that fibroblasts play a role in the
inflammatory immune response.
By using CD15 and CD68 antigens as markers, we ob-
served a significant increase in monocyte-macrophages
in the small bowel mucosa of IgAN patients. In good
agreement with the role of these cells in initiating and reg-
ulating the immune response, we observed a significant
correlation between the amount of monocyte-
macrophages and CD3+ cells. In IgAN patients, we
also found an interesting correlation between the
number of CD15+ cells and the degree of proteinuria.
As to the macrophages, only a trend was seen (rs =
0.460, P = 0.073). Previously, a relationship between
glomerular monocytes and the degree of proteinuria
has been described in IgAN [34, 35]. COX-2 expres-
sion in CD15+ cells suggests activation. Activation of
monocyte-macrophages is a complex phenomenon and it
is not known what mechanisms in IgAN affect the tissue
infiltration of these cells. It is, however, possible that
activated monocytes find their way both to the glomeruli
and the small bowel.
In patients with IgAN there was a significant cor-
relation between CD68+ cells and COX-2 expression
in the lamina propria. In confocal microscopy, COX-2
was also seen to be coexpressed in many CD68+ cells.
COX-2 mRNA has been shown to be induced in acti-
vated macrophages, and the expression is regulated by
cytokines during activation [36, 37]. Increased mucosal
levels of interleukin-1 (IL-1) are seen in both acute and
chronic intestinal inflammation [24, 38, 39]. One of the
effects of IL-1 is induction of the localized synthesis and
release of eicosanoid mediators through COX pathways
[24, 33, 40, 41].
In many CD3+ cells, COX-2 expression was observed
in confocal microscopy. The cellular location of COX-
2 protein was similar to that described earlier [42, 43].
There was also significant correlation between CD3+ and
COX-2–positive cells both in the epithelium and in the
lamina propria. According to the results of previous stud-
ies [10, 11, 44, 45], activation of T cells induces COX-2
expression. On this basis, the remarkable proportion of
lymphocytes present in the small bowel lamina propria of
IgAN patients can be regarded as being activated cells.
Using a transgenic animal model, it has been shown that
T-cell–mediated intestinal inflammation can cause typical
features of IgAN, including an increase in the circulating
IgA [46]. In our study, we demonstrate that in human
IgAN the amount intestinal lymphocytes and their ac-
tivation markers correlate significantly with serum IgA
and hematuria.
Despite increased numbers of lymphocytes in the ep-
ithelium and the lamina propria, no proliferation of these
cells was seen; Ki-67 antigen was only expressed in the
nuclei of cryptal epithelial cells. Several lymphocytes,
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however, proved to be CD45RO+ memory T cells, which
represent a primed population responding to recall anti-
gens. Intestinal lamina propria T cells usually have a high
expression of CD45RO antigen and in the inflammatory
bowel disease, further increase in the expression has been
observed [47]. There is no studies concerning the small
bowel of IgAN patients but a significant increase in the
number of circulating CD45RO+ cells has been described
[8, 48] and it also appears that serum levels of IgA are pos-
itively correlated with the number of memory cells [48].
On the basis of DR positivity, activation of the memory
cells has also been suggested [8]. In our study, COX-2
expression in the memory cells suggests activation, albeit
the original activation site remains to be confirmed.
According to the concept of the common mucosal im-
mune system [49], mucosal presentation of antigens can
lead to dissemination of the immune response. Link-
ing of the mucosal and systemic immune systems occurs
through the mucosa-marrow axis [50], and some cells, in-
stead of homing to the mucosal sites, can be driven to the
sites of humoral antibody production [51, 52]. The entry
of mucosal immunocytes into the systemic sites can lead
to mucosal-specific immunoglobulin release into the cir-
culation [52]. Interestingly, it appears that Helicobacter
pylori infection can result in markedly higher systemic
levels of both IgA1 and IgG in IgAN patients versus
healthy individuals [52]. An increase in small bowel mu-
cosal IgA plasma cells has not been observed in IgAN
[53, 54], whereas increased numbers of polymeric IgA1-
producing plasma cells have been found in the bone
marrow [55, 56]. In the present study, no difference was
observed in IgA producing plasma cells between IgAN
and controls. However, a significant correlation was seen
between IgA plasma cells and serum IgA, albeit no cor-
relation was observed between polymeric IgA producing
plasma cells and serum IgA. These data are in line with
an old suggestion that continuously present mucosal anti-
gens can affect antibody production in the bone marrow
[57]. H. pylori could well represent this kind of mucosal
challenge, albeit IgAN is, however, most probably depen-
dent on several different mucosal antigenic stimulations.
The production of J chains in IgAN patients has been
shown to be decreased in the gut and increased in the
bone marrow [9]. This is in good agreement with the
present results demonstrating that the proportion of J
chain producing plasma cells is significantly decreased in
IgAN. A significant negative correlation between COX-
2 expression in the lamina propria and polymeric IgA
production suggests that the production of polymeric
IgA cannot respond to the increase in inflammation.
A decrease in polymeric IgA production can debilitate
the transepithelial transport through the polymeric im-
munoglobulin receptor and allow an increase in the pen-
etration of luminal antigens [58]. Increased numbers of
lymphocytes and monocyte-macrophages together with
COX-2 expression, described in the present study, may
well be a manifestation of persistent or recurrent anti-
genic stimuli [59]. In addition to the intestinal mucosa,
increased inflow of antigens can also affect the systemic
compartment [52, 57, 58]. A great increase in the systemic
production of IgA1 is not necessary to cause elevated
serum levels. If IgA is abnormally glycosylated for one
reason or another, the glycosylation defect is enough to
decrease its hepatic clearance and promote its mesangial
binding [60, 61].
CONCLUSION
Our present results indicate that in the small bowel mu-
cosa of IgAN patients, the proportion of polymeric IgA
producing plasma cells is decreased. In the small bowel,
there is also an inflammation that is reflected in an in-
crease in the number of inflammatory cells and increased
mucosal COX-2 expression. The production of COX-2
in the mucosal cells suggests their activation and COX-
2–dependent prostaglandin production. Active intestinal
inflammation in IgAN strongly relates with serum IgA,
proteinuria, and hematuria. It also seems probable that
subepithelial fibroblasts are involved in the inflammatory
process.
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